- Thromboprophylaxis in Ambulatory Cancer Patients: Results of the AVERT TrialFebruary 25, 2019
Drs. May and Moll discuss the AVERT Trial, which provides a novel approach to thromboprophylaxis in ambulatory patients with cancer.
- Monitoring Treatment Response in Multiple Myeloma: Wading Into the Deep EndFebruary 21, 2019
Drs. Ouseph and Kim discuss the utility of MRD measurements in the context of MM and the use of deep sequencing of clonotypic rearrangements by NGS to achieve greater analytical sensitivity in assessing MRD, and thus predicting outcomes in myeloma.
- Beating AML: Know Your EnemyFebruary 20, 2019 | Steven Lane, MBBS, PhD, FRACP, FRCPA
Dr. Lane stresses the importance of understanding disease, in this case acute myeloid leukemia, and discusses results of the Beat AML Trial.
- The Cellular Pathway of Leukemic Transformation in MDS: It's the Stem Cells, Stupid!February 19, 2019
Dr. Mead and Dr. Rodriguez-Meira discuss a study that expands the understanding of the evolutionary processes leading to leukemic transformation of MDS.
- A New Standard Emerges: Rational Use of Venetoclax to Inhibit BCL-2 Allows Treatment of AML In Older PatientsFebruary 13, 2019 | Amy DeZern, MD, MHS
Dr. DeZern discusses two studies that show improved outcomes for older patients with AML using a venetoclax and hypomethylating agents combination.
- Comprehensive Genomic Classification of Pediatric Mixed-Phenotype Acute LeukemiaFebruary 13, 2019
Dr. O'Dwyer and Dr. Becker review several reports that provide a comprehensive genomic analysis of pediatric mixed phenotype acute leukemia, comparing its "genomic landscape" to other pediatric acute leukemia subtypes.
- Defining the Poor Prognosis of Double-Hit Lymphomas: Implications for Diagnosis and TherapyFebruary 13, 2019 | Caron A. Jacobson, MD
Dr. Jacobson discusses the genetic and molecular factors that associate with the inferior outcomes seen in double-hit lymphomas, identifying new targets and treatment options in these diseases.
- Keeping Your ESCHELONs StraightFebruary 13, 2019 | Brad Kahl, MD
Dr. Kahl discusses the ESCHELON-2 study, a CD30+ T-cell lymphoma trial which used a "repeal and replace" strategy, eliminating vincristine from the experimental regimen and substituting in BV.
- The Microbiome: A New Variable in Multiple Myeloma Disease ProgressionFebruary 13, 2019
Drs. Shen, Sklavenitis-Pistofidis, and Ghobrial discuss studies that look to find the best therapeutic intervention for patients with high-risk smoldering multiple myeloma to prevent disease progression.
- Hydroxyurea for Children With Sickle Cell Anemia in Sub-Saharan Africa: The Child That Comes and Goes Away Can Come to Stay With HydroxyureaFebruary 07, 2019 | Ifeyinwa (Ify) Osunkwo, MD, MPH
Dr. Osunkwo discusses the REACH Trial, which demonstrates the safety and efficacy of hydroxyurea use among children in four sub-Saharan African countries, and its implications for treating sickle cell disease.